301. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
- Author
-
Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y, Feng WH, Li YY, and Cao XC
- Subjects
- Biphenyl Compounds administration & dosage, Breast Neoplasms metabolism, Caspase 3 metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Synergism, Female, Humans, Nitrophenols administration & dosage, Piperazines administration & dosage, Piperazines pharmacology, Poly(ADP-ribose) Polymerases metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, Sulfonamides administration & dosage, bcl-2-Associated X Protein metabolism, bcl-X Protein metabolism, Antineoplastic Agents pharmacology, Apoptosis drug effects, Biphenyl Compounds pharmacology, Breast Neoplasms pathology, Cisplatin pharmacology, Nitrophenols pharmacology, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Sulfonamides pharmacology
- Abstract
Objective: To study the effect of ABT-737 combined with cisplatin on apoptosis of breast cancer cell line T47D cells., Methods: T47D cells cultured in vitro was used for this experiment. Cell proliferation was measured by MTT assay. The expression of apoptosis-related protein was determined by Western blot. Morphological changes of apoptotic cells were observed by fluorescence microscopy. The apoptosis rate was examined by flow cytometry., Results: The MTT assay showed that ABT-737 significantly decreased the IC(50) of cisplatin in T47D cells [(26.00 ± 1.41) µmol/L of single cisplatin vs. (13.00 ± 1.11) µmol/L of combination (ABT-737 + cisplatin)]. As a single agent, ABT-737 did not inhibit the proliferation of T47D cells, but enhanced the inhibitory effect of cisplatin in a dose-dependent manner. The detection of the cleavage of PARP showed that ABT-737 lowered the doses of cisplatin to induce apoptosis and shortened the induction time of apoptosis in T47D cells. Compared with the single use of cisplatin, the combination of ABT-737 and cisplatin accelerated the cleavage of PARP and caspase3, but did not alter the expression levels of Bcl-2, Bcl-X(L), and Bax. Both flow cytometry and fluorescence microscopy showed that ABT-737 combined with cisplatin significantly increased the apoptosis induction in T47D cells (2.3% ± 0.1 % in the control, 30.0% ± 0.8% in the cisplatin alone, and 49.0% ± 0.5% in the cisplatin + ABT-737 groups, P < 0.05)., Conclusion: The Bcl-2 inhibitor ABT-737 can significantly enhance cisplatin-induced apoptosis in human breast cancer T47D cells in vitro.
- Published
- 2011